黑料官网

header-logo
GettyImages-609179959-hero
headshot

Lubna N. Chaudhary, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Breast Care Center - Clinical Cancer Center - Froedtert Hospital
  • Cancer Center - Froedtert Menomonee Falls Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Urdu, Hindi

Breast Care Center

Cancer Center - Froedtert Menomonee Falls Hospital

Clinical Cancer Center - Froedtert Hospital

New Patient Appointments - Breast

Education

  • MD - Doctor of Medicine

Biography

Lubna Chaudhary, MD, MS, is an assistant professor of medicine at the 黑料官网 Division of Hematology and Oncology. She graduated from King Edward Medical College, Pakistan. She completed residency in Internal Medicine from West Virginia University and a fellowship in hematology/oncology from Froedtert & the 黑料官网 (黑料官网). She also obtained a Masters degree in Clinical and Translational Science through CTSI at 黑料官网. Dr. Chaudhary is board certified in Internal Medicine and Medical Oncology. She has authored numerous peer reviewed publications and is actively involved in breast cancer clinical trials.

Research Interests

Dr. Chaudhary's primary research focus is to understand and study breast cancer tumor biology, association of receptor status with patient outcomes and breast cancer developmental therapeutics. She is the primary investigator of many ongoing breast cancer clinical trials. She treats breast cancer patients at the Froedtert & the 黑料官网 Breast Care Center as well as at Froedtert Menomonee Falls Hospital. She is also responsible for co-management of the Hereditary Cancer Management clinic, with a specific focus on breast cancers.

Publications

  • (Patel R, Weil E, Bugamelli S, Carroll E, Steinke K, Stockhausen E, Burfeind J, Mooney C, Retseck J, Sriram D, Deininger J, Halbach A, Sweeney M, Kamaraju S, Chaudhary LN, Cheng YC.) Breast Cancer Res. 2025 Aug 18;27(1):147 PMID: 40826432 PMCID: PMC12360005 SCOPUS ID: 2-s2.0-105013522509 08/19/2025

  • (Kumar R, Duyar-Ayerdi S, Sundaresan A, Srinivasasainagendra V, Pedamallu CS, Behring M, Chandrashekar DS, Eltoum IE, Varambally S, Tiwari HK, Shrestha S, Auer PL, Chaudhary LN, Kirby JR, Yates C, Manne U, Ojesina AI.) NPJ Breast Cancer. 2025 Aug 08;11(1):87 PMID: 40781241 PMCID: PMC12334597 SCOPUS ID: 2-s2.0-105012896561 08/09/2025

  • (Cohen LN, Rogers CC, Lloren JIC, Kamaraju S, Chaudhary LN, Huang CC, Cobb AN, Singh P, Kong AL, Teshome M, Cortina CS.) Breast Cancer Res Treat. 2025 Aug;212(3):531-543 PMID: 40459676 PMCID: PMC12213117 SCOPUS ID: 2-s2.0-105007155274 06/03/2025

  • (Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, Elijah J, George A, Attwood K, Shaikh SS, Chaudhary LN, Abdou Y, Gandhi S.) JCO Oncol Pract. 2025 May;21(5):620-628 PMID: 39353151 PMCID: PMC12165508 SCOPUS ID: 2-s2.0-105005564477 10/03/2024

  • (Kamaraju S, Fowler AM, Tarima S, Chaudhary LN, Burkard ME, Giever T, Cheng YC, Parkes A, Lange CA, Pipp-Dahm M, Hegeman R, Siddiqui N, Stella A, Rajguru S, Twaroski K, Zurbriggen L, Jorns JM, Rui H, Keigley QJ, Perlman SB, Salem K, Bradshaw TJ, Sahmoud T, Wisinski K.) Clin Breast Cancer. 2025 Apr;25(3):251-260 PMID: 39824712 SCOPUS ID: 2-s2.0-85215561512 01/18/2025

  • (Ibrahim EH, Chaudhary L, Cheng YC, Sosa A, An D, Charlson J.) Radiol Oncol. 2025 Mar 01;59(1):79-90 PMID: 40014780 PMCID: PMC11867570 SCOPUS ID: 2-s2.0-86000078216 02/27/2025

  • (Krishnan J, Patel A, Roy AM, Alharbi M, Kapoor A, Yao S, Khoury T, Hong CC, Held N, Chakraborty A, Kaliniski P, Salman A, Catalfamo K, Attwood K, Kirtani V, Shaikh SS, Chaudhary LN, Gandhi S.) Clin Breast Cancer. 2024 Dec;24(8):e701-e711.e2 PMID: 39198116 SCOPUS ID: 2-s2.0-85202494820 08/31/2024

  • (Valencia EA, Cortina CS, Cobb AN, Chaudhary LN, Kelly T, Kong AL.) Ann Surg Open. 2024 Sep;5(3):e465 PMID: 39310356 PMCID: PMC11415127 09/23/2024

  • (Jorns JM, Sun Y, Kamaraju S, Cheng YC, Kong A, Yen T, Patten CR, Cortina CS, Chitambar CR, Rui H, Chaudhary LN.) J Pers Med. 2024 Apr 29;14(5) PMID: 38793060 PMCID: PMC11121947 SCOPUS ID: 2-s2.0-85194400127 05/25/2024

  • (Gonzalez T, Nie Q, Chaudhary LN, Basel D, Reddi HV.) Cancer Genet. 2024 Apr;282-283:1-8 PMID: 38134587 SCOPUS ID: 2-s2.0-85180559446 12/22/2023

  • (Pierro M, Zurko J, Szabo A, Cheng YC, Kamaraju S, Burfeind J, Retseck J, Chitambar CR, Chaudhary LN.) WMJ. 2023 Dec;122(5):418-421 PMID: 38180937 SCOPUS ID: 2-s2.0-85181850540 01/05/2024

  • (Alaklabi S, Roy AM, Chaudhary LN, Gandhi S.) Explor Target Antitumor Ther. 2023;4(6):1301-1309 PMID: 38213539 PMCID: PMC10776593 01/12/2024

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.